+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Blood Plasma Derivatives Market by Source, End User, Distribution Channel, Product Type, Application - Global Forecast to 2030- Product Image
Blood Plasma Derivatives Market by Source, End User, Distribution Channel, Product Type, Application - Global Forecast to 2030- Product Image
Sale

Blood Plasma Derivatives Market by Source, End User, Distribution Channel, Product Type, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010980
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Blood Plasma Derivatives Market grew from USD 523.83 million in 2024 to USD 576.03 million in 2025. It is expected to continue growing at a CAGR of 9.88%, reaching USD 922.24 million by 2030.

Unveiling the Dynamics of the Blood Plasma Therapeutics Market

The blood plasma derivatives market stands at a crossroads of innovation, clinical necessity, and global supply chain evolution. As demand for life-saving therapies for hemophilia, primary immunodeficiency, and neurological disorders accelerates, stakeholders across the value chain-from biopharmaceutical developers to treatment centers and home care providers-are compelled to understand the forces shaping this complex landscape. Recent advances in recombinant technologies have introduced new therapeutic options, while longstanding plasma-derived products continue to serve as the backbone of treatment protocols worldwide.

This executive summary synthesizes critical insights drawn from a rigorous research framework, spotlighting transformative trends, regulatory influences, and competitive dynamics that will steer market trajectories in the short to mid term. By examining source variations, end-user behaviors, distribution channels, and product portfolios alongside regional nuances, this report equips decision-makers with the clarity required to drive strategic investments and operational excellence. As healthcare budgets tighten and patient populations expand, the need for data-backed guidance has never been more acute. This introduction sets the stage for a deeper exploration of the market’s defining shifts and actionable recommendations that will enable your organization to thrive in an evolving environment.

Evolutionary Forces Reshaping the Blood Plasma Derivatives Sector

Throughout the last decade, the blood plasma derivatives sector has undergone seismic shifts driven by technological breakthroughs and shifting patient needs. Recombinant factor VIII and IX therapies have matured beyond proof-of-concept, offering consistent supply and reduced reliance on donor plasma. At the same time, plasma-derived immunoglobulins have diversified their clinical footprint, moving from traditional primary immunodeficiency applications to address neurological disorders such as chronic inflammatory demyelinating polyneuropathy.

Concurrently, digital transformation has permeated distribution channels, streamlining order fulfillment via online pharmacies and specialist clinics while enhancing traceability through advanced serialization technologies. Regulatory bodies worldwide are accelerating approval pathways for novel biologics, fostering a competitive environment where innovation and speed to market are pivotal. Strategic partnerships and licensing agreements have become commonplace as leading players seek to bolster their portfolios without incurring the full burden of R&D expenditure. These evolutionary forces are redefining the competitive landscape, demanding agility and strategic foresight from all stakeholders.

Assessing the Impact of 2025 US Tariffs on Global Supply Chains

The implementation of new U.S. tariffs in 2025 marks a critical inflection point for global supply chains of blood plasma derivatives. Increased duties on imported plasma-derived products have prompted manufacturers to reassess sourcing strategies and negotiate terms with domestic plasma collection networks. The result is a reconfiguration of cost structures that directly impacts pricing negotiations with payers and healthcare providers.

In response, several global firms have initiated partial onshore manufacturing expansions, leveraging existing capacities in North America to mitigate tariff exposures. However, redeploying production lines carries its own challenges, including stringent Good Manufacturing Practice requirements and the need to secure adequate plasma supply volumes. Downstream, treatment centers and hospitals are bracing for potential reimbursement disputes as incremental costs filter through to invoices. The cumulative effect of these tariffs extends beyond fiscal pressures, triggering strategic realignments and ushering in a period of operational recalibration for industry leaders.

Deep Dive into Market Segments Driving Growth

A nuanced understanding of market segmentation is essential to pinpointing high-margin opportunities and designing targeted market access strategies. On the basis of source, the market bifurcates into plasma-derived and recombinant products, with the latter further dissected into Factor IX and Factor VIII variants. Each source type demands differentiated supply chain logistics, regulatory dossiers, and quality assurance protocols.

Segmenting by end user reveals distinct adoption patterns across hemophilia treatment centers, home care settings, and hospitals. Hemophilia treatment centers prioritize specialized factor concentrates and comprehensive patient support programs, while home care channels emphasize patient self-administration kits and remote monitoring services. Hospitals, by contrast, maintain a broader formulary, balancing acute care demands with immunoglobulin infusion services.

Distribution channels underscore the growing importance of hospital pharmacies, online pharmacies, retail outlets, and specialist clinics. Hospital pharmacies serve as critical hubs for inpatient and outpatient administrations, whereas online pharmacies have surged in prominence through direct-to-patient models that offer convenience and discrete delivery. Retail pharmacies continue to support maintenance therapies, and specialist clinics drive demand for high-touch infusion services.

Turning to product type, the spectrum spans albumin formulations, coagulation factors, and immunoglobulins. Coagulation factors encompass Factor IX, Factor VIII, and fibrin sealants tailored to surgical and trauma applications, whereas immunoglobulins subdivide into hyperimmune, intravenous, and subcutaneous preparations. Each category carries unique pricing, administration, and storage considerations.

Finally, application-based analysis distinguishes hemophilia treatment, neurological disorders, and primary immunodeficiency segments. Hemophilia treatment remains the largest single application, yet neurological disorder therapies are registering above-average compound adoption rates as off-label uses and emerging clinical evidence widen the scope of immunoglobulin utilization.

Regional Dynamics and Market Potential Across Key Geographies

Geographic dynamics shape competitive positioning and growth potential across the Americas, Europe Middle East & Africa, and Asia-Pacific regions. In the Americas, established plasma collection networks and mature reimbursement frameworks underpin robust demand for both plasma-derived and recombinant therapies. Market leaders leverage well-developed distribution infrastructures, while emerging players explore partnerships to gain national formulary access.

The Europe Middle East & Africa region presents a tapestry of regulatory environments, reimbursement models, and healthcare delivery systems. Western European nations drive adoption through centralized procurement tenders and national hemophilia registries, whereas select markets in the Middle East are investing heavily in plasma collection facilities to reduce import dependencies. Africa remains an evolution frontier, with expanding public health initiatives gradually incorporating immunoglobulin therapies into treatment protocols.

In the Asia-Pacific region, rising healthcare expenditures and growing awareness of rare diseases are translating into accelerated market growth. Japan and Australia maintain stringent regulatory requirements but reward innovative therapies with expedited pathways. Rapidly expanding markets such as China and India are scaling plasma collection and local manufacturing capacities, spurred by supportive government policies and increasing patient advocacy efforts. These regional dynamics underscore the need for tailored strategies that align with local regulatory, economic, and cultural factors.

Competitive Landscape and Strategic Positioning of Leading Players

The competitive arena is anchored by a handful of global biopharmaceutical companies that boast extensive portfolios of both plasma-derived and recombinant products. These industry leaders distinguish themselves through integrated plasma collection networks, state-of-the-art manufacturing facilities, and robust pipelines fueled by strategic R&D collaborations. Mid-tier players compete through niche specialization, often focusing on high-value product categories such as subcutaneous immunoglobulins or advanced recombinant factor therapies.

Innovative start-ups and biotech disruptors are also asserting their presence, frequently entering licensing agreements with established manufacturers to leverage commercial expertise. Mergers and acquisitions remain a core growth tactic, enabling acquirers to expand geographic footprints and diversify product lines. Meanwhile, strategic partnerships between specialty clinics and academic centers are catalyzing novel clinical data generation, setting the stage for next-generation formulations and delivery methods. Collectively, these competitive dynamics foster an environment where agility, scale, and innovation converge to define market leadership.

Strategic Imperatives for Capitalizing on Market Opportunities

To capitalize on emerging opportunities, industry leaders should prioritize expanding recombinant pipelines while maintaining optimized plasma collection operations. Investing in flexible manufacturing platforms will enable rapid scale-up in response to supply chain disruptions or tariff shifts. Strengthening partnerships with hemophilia treatment centers and home care providers can enhance patient engagement and support service differentiation.

Embracing digital distribution models-particularly online pharmacies and remote monitoring tools-will address patient convenience demands and foster adherence. Proactive engagement with regulatory authorities to secure conditional approvals or accelerated review designations can expedite time to market for breakthrough therapies. Additionally, pursuing localized manufacturing alliances in high-growth regions will mitigate geopolitical risk and align product portfolios with regional pricing structures.

Finally, leveraging real-world evidence and patient registries will underscore clinical and economic value, reinforcing reimbursement negotiations. By adopting a multidimensional strategic framework, companies can balance innovation with operational resilience and secure sustainable growth in an increasingly competitive field.

Rigorous Research Framework Underpinning Market Insights

This analysis is built upon a rigorous research framework that integrates both primary and secondary data sources. Expert interviews with key opinion leaders, C-suite executives, and supply chain specialists provided firsthand insights into strategic priorities and operational challenges. These qualitative inputs were supplemented by surveys targeting clinicians and patient advocacy groups to capture evolving treatment patterns and unmet needs.

Secondary research drew from regulatory filings, peer-reviewed journals, trade publications, and company disclosures. Financial reports and procurement data illuminated pricing dynamics and volume trends, while policy documents offered context on regulatory shifts and tariff impacts. All data points were subjected to triangulation, ensuring consistency across sources and methodologies.

Quantitative analysis leveraged historical trend evaluation and cross-segment correlations to identify growth drivers without engaging in market sizing or forecasting. Each conclusion underwent internal validation by subject matter experts to confirm factual accuracy and relevance. This robust approach underpins the insights presented herein and offers a transparent roadmap for future updates.

Consolidating Insights for Informed Decision Making

In synthesizing the multifaceted drivers, competitive dynamics, and regional specificities of the blood plasma derivatives market, this executive summary furnishes decision-makers with actionable clarity. From the ramifications of U.S. tariffs to the nuanced segmentation across source types, end users, and applications, each insight contributes to a cohesive narrative that guides strategic planning.

As innovation accelerates and healthcare landscapes continue to evolve, stakeholders equipped with these robust insights will be better positioned to navigate complexity and capture emerging value pools. By applying the recommended strategic imperatives and leveraging our thorough research framework, companies can optimize their market approaches, mitigate risks, and achieve sustainable growth.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Source
    • Plasma Derived
    • Recombinant
      • Factor IX
      • Factor VIII
  • End User
    • Hemophilia Treatment Centers
    • Home Care
    • Hospitals
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacies
    • Retail Pharmacy
    • Specialist Clinics
  • Product Type
    • Albumin
    • Coagulation Factor
      • Factor IX
      • Factor VIII
      • Fibrin Sealant
    • Immunoglobulin
      • Hyperimmune
      • Intravenous
      • Subcutaneous
  • Application
    • Hemophilia Treatment
    • Neurological Disorders
    • Primary Immunodeficiency
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • CSL Limited
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • Biotest AG
  • LFB S.A.
  • Bio Products Laboratory Limited
  • Shanghai RAAS Blood Products Co., Ltd.
  • China Biologic Products Holdings, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Blood Plasma Derivatives Market, by Source
8.1. Introduction
8.2. Plasma Derived
8.3. Recombinant
8.3.1. Factor IX
8.3.2. Factor VIII
9. Blood Plasma Derivatives Market, by End User
9.1. Introduction
9.2. Hemophilia Treatment Centers
9.3. Home Care
9.4. Hospitals
10. Blood Plasma Derivatives Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacies
10.4. Retail Pharmacy
10.5. Specialist Clinics
11. Blood Plasma Derivatives Market, by Product Type
11.1. Introduction
11.2. Albumin
11.3. Coagulation Factor
11.3.1. Factor IX
11.3.2. Factor VIII
11.3.3. Fibrin Sealant
11.4. Immunoglobulin
11.4.1. Hyperimmune
11.4.2. Intravenous
11.4.3. Subcutaneous
12. Blood Plasma Derivatives Market, by Application
12.1. Introduction
12.2. Hemophilia Treatment
12.3. Neurological Disorders
12.4. Primary Immunodeficiency
13. Americas Blood Plasma Derivatives Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Blood Plasma Derivatives Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Blood Plasma Derivatives Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. CSL Limited
16.3.2. Grifols, S.A.
16.3.3. Takeda Pharmaceutical Company Limited
16.3.4. Octapharma AG
16.3.5. Kedrion S.p.A.
16.3.6. Biotest AG
16.3.7. LFB S.A.
16.3.8. Bio Products Laboratory Limited
16.3.9. Shanghai RAAS Blood Products Co., Ltd.
16.3.10. China Biologic Products Holdings, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BLOOD PLASMA DERIVATIVES MARKET MULTI-CURRENCY
FIGURE 2. BLOOD PLASMA DERIVATIVES MARKET MULTI-LANGUAGE
FIGURE 3. BLOOD PLASMA DERIVATIVES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BLOOD PLASMA DERIVATIVES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BLOOD PLASMA DERIVATIVES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRIN SEALANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HYPERIMMUNE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 55. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 56. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 57. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 60. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 61. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 62. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 64. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 65. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 69. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 70. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 105. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 106. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 109. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 110. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 111. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 113. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 114. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 117. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 118. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 119. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 129. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 130. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 133. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 134. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 135. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 137. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 138. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 142. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 143. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 169. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 170. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 173. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 174. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 175. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 185. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 186. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 189. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 190. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 191. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 193. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 194. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 197. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 198. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 199. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 217. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 218. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 221. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 222. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 223. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 225. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 226. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 230. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 231. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 241. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 242. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 245. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 246. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 247. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 248. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 249. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 250. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 254. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 255. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 273. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 274. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 275. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 279. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 280. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 282. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 283. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 286. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 287. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 288. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 289. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 290. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 291. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 294. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 295. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 296. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 321. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 322. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 323. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 325. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 326. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2030 (USD MILLION)
TABLE 327. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD MILLION)
TABLE 328. THAILAND BLOOD PLAS

Companies Mentioned

The companies profiled in this Blood Plasma Derivatives market report include:
  • CSL Limited
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • Biotest AG
  • LFB S.A.
  • Bio Products Laboratory Limited
  • Shanghai RAAS Blood Products Co., Ltd.
  • China Biologic Products Holdings, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 576.03 Million
Forecasted Market Value ( USD ) by 2030 $ 922.24 Million
Compound Annual Growth Rate9.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Blood Plasma Derivatives Market Size, Share, Trends and Forecast by Type, Application, End User, and Region, 2025-2033 - Product Image

Blood Plasma Derivatives Market Size, Share, Trends and Forecast by Type, Application, End User, and Region, 2025-2033

  • Report
  • 149 Pages
  • Global
From
Blood Plasma Derivatives Market Report 2025 - Product Image

Blood Plasma Derivatives Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Blood Plasma Derivatives Global Market Opportunities and Strategies to 2033 - Product Image

Blood Plasma Derivatives Global Market Opportunities and Strategies to 2033

  • Report
  • 327 Pages
  • Global
From
Bovine Blood Plasma Derivatives - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Bovine Blood Plasma Derivatives - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 120 Pages
  • Global
From
Blood Plasma Derivatives Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Blood Plasma Derivatives Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 93 Pages
  • Global
From

About the Plasma Derivative Market

The Plasma Derivative market is a subset of the Blood Banking industry, which involves the collection, processing, and distribution of human blood and its components. Plasma derivatives are products derived from human plasma, such as albumin, immunoglobulins, and clotting factors. These products are used to treat a variety of medical conditions, including hemophilia, immune deficiencies, and shock. Plasma derivatives are typically collected from healthy donors and processed in a laboratory setting. The process involves separating the plasma from the other components of the blood, such as red and white blood cells. The plasma is then further processed to create the desired product. The Plasma Derivative market is highly regulated, with stringent safety and quality standards in place to ensure the safety of the products. Companies in the market include CSL Behring, Grifols, Octapharma, Kedrion, and Biotest. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.